Express Healthcare
Home  »  News  »  TOSH launches stem cell and regenerative medicine unit in orthopaedics

TOSH launches stem cell and regenerative medicine unit in orthopaedics

98
Read Article

It will be headed by Dr AA Shetty and Dr Seok Jung Kim will be the scientific adviser

Chennai-based Trauma & Orthopaedic Speciality Hospital (TOSH) has launched a stem cell and regenerative medicine unit in orthopaedics. Reportedly, this unit headed by Dr AA Shetty and Dr Seok Jung Kim as the scientific adviser will offer stem cell therapies for knee arthritis, fracture non-unions, avascular necrosis of hip, sport injuries and chronic ligament tears. A dedicated exclusive operation theatre has been opened for stem cell procedures.

“TOSH has introduced new single stage technique in 2012 and many patients underwent stem cell surgeries over the past two years. Encouraged by the good results, TOSH has decided to set up a stem cell and regenerative medicine unit in orthopaedics to benefit large number of orthopaedic patients,” said Dr SH Jaheer Hussain, Specialist in Joint Replacement, Director, TOSH.

On the affordability and effectiveness of the procedures, Dr V Thirumal Selvan, Specialist in Joint Replacement & Arthroscopy, Director, TOSH, said “The stem cell treatment sets a new bench mark in the treatment of knee arthritis and the cost is significantly less (costing around Rs. 1 lakh) when compared to joint replacement. This surgery will help young, middle aged and elderly patients with early arthritis. The stem cell kit used for this technique is FDA/CE (Food and Drug Administration/European Conformity) approved and is safe and effective.”

“In the new single stage technique, the stem cells are harvested and centrifuged in the operation theatre itself. The stem cell concentrate is then mixed with a special fibrin gel and fixed directly at the site of cartilage damage through keyhole surgery. As the fixation is immediate, the patient is allowed to walk the very next day of surgery,” said Dr Shetty, Head, Orthopaedics.

Comments are closed.